United Therapeutics CEO sells $5.5M in stock

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), sold 9,500 shares of the company’s common stock on October 23, 2026, for a total value of approximately $5.54 million. The shares were sold at prices ranging from $577.6774 to $587.9997 per share. The sale comes as the stock trades near its 52-week high of $609.35, with shares delivering a strong 40% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. The company maintains a market capitalization of $25.41 billion and trades at a P/E ratio of 21.02.

The sale followed the exercise of 9,500 stock options on the same day. These options were acquired at an exercise price of $117.76 per share, totaling approximately $1.12 million. The options had vested in equal one-third installments on March 15, 2021, 2022, and 2023.

Both the option exercise and the subsequent sale of common stock were executed pursuant to a pre-arranged 10b5-1 trading plan. This plan was adopted by Ms. Rothblatt on November 7, 2025, and is set to continue until either the exercise of 1,734,410 stock options (all expiring on March 15, 2027) or December 31, 2026, whichever comes first.

Following these transactions, Ms. Rothblatt indirectly holds 324,443 shares of common stock through a family trust where she shares investment power and is a beneficiary. She also holds 166,910 stock options indirectly through a family trust. For deeper insights into UTHR’s valuation and financial health, InvestingPro offers comprehensive analysis including Pro Research Reports for over 1,400 US equities.

In other recent news, United Therapeutics reported a revenue miss of approximately 3% in its second-quarter results, prompting BofA Securities to lower its price target to $559 while maintaining a Neutral rating. The company has also decided not to affirm its previous Tyvaso sales guidance. In legal developments, United Therapeutics reached a settlement agreement with Liquidia Technologies, resolving all litigation between the two companies. As part of the settlement, Liquidia will pay United Therapeutics $380.7 million and make changes to its YUTREPIA label.

Following these legal outcomes, Jefferies raised its price target for United Therapeutics to $728, maintaining a Buy rating. Cantor Fitzgerald reiterated an Overweight rating with a $700 price target after United Therapeutics won on two patent claims related to its Tyvaso franchise. BTIG upgraded the company to Buy from Neutral, setting a price target of $728 due to the favorable initial trial decision in the ’327 patent case. Meanwhile, Goldman Sachs initiated coverage with a Sell rating and a price target of $321, citing a declining base business. These recent developments highlight a range of analyst perspectives on United Therapeutics.